Prognosis
U.S. Halts Shipments of Lilly Antibody Combo, Citing Resistance in Patients
- Combination may not be effective against gamma, beta variants
- Health officials urge use of other antibody treatments instead
This article is for subscribers only.
U.S. health officials paused distribution of Eli Lilly & Co.’s combination antibody therapy because of fears it won’t combat two increasingly common coronavirus variants.
Resistance to the antibody treatment was detected among the gamma and beta variants of the virus, according to a statement from the Department of Health and Human Services. Medical providers should use other antibody treatments from Regeneron Pharmaceuticals Inc. and GlaxoSmithKline Plc instead, they said.